Search Result

11 search results for Histiocytic Neoplasms

Cancer Care and Humanitarian Crises

Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma Kidney Cancer Melanoma: Cutaneous Melanoma, Myelodysplastic Syndromes Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Myeloproliferative Neoplasms Neuroblastoma Neuroendocrine and Adrenal Tumors Non-Small Cell, Uterine Neoplasms Vulvar Cancer Waldenström Macroglobulinemia / Lymphoplasmacytic Lymphoma Wilms, Myeloproliferative Neoplasms Nasopharyngeal Cancer Nausea and Vomiting Neuroendocrine Tumors Non-Small

https://www.nccn.org/global/what-we-do/cancer-care-and-humanitarian-crises

Submission Request Form

Factors - 3.2024 Hepatobiliary Cancers - 1.2023 Hepatocellular Carcinoma - 2.2023 Histiocytic Neoplasms - 1.2023 Hodgkin Lymphoma - 2.2024 Kaposi Sarcoma - 1.2024 Kidney Cancer - 2.2024 Lung, Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions - 1.2024 Myeloproliferative Neoplasms - 1.2024 Neuroblastoma - 1.2024 Neuroendocrine and Adrenal Tumors - 1.2023 Non, Carcinoma - 1.2024 Uterine Neoplasms - 1.2024 Vulvar Cancer - 3.2024 Waldenström

https://www.nccn.org/guidelines/submissions-request-to-the-guidelines-panels/submission-request-form

Guidelines Panels

Cancers Panel Histiocytic Neoplasms, Myeloproliferative Neoplasms Panel

https://www.nccn.org/guidelines/guidelines-panels-and-disclosure/disclosure-panels

Treatment by Cancer Type

Version: 2.2023 Histiocytic Neoplasms, Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Version: 1.2024 Myeloproliferative Neoplasms, Neoplasms Version: 1.2024 Vulvar Cancer

https://www.nccn.org/guidelines/category_1

Permission to Cite or Use NCCN Content

Hematopoietic Growth Factors Hepatobiliary Cancers Hepatocellular Carcinoma Histiocytic Neoplasms, and Neck Cancers Hepatobiliary Cancers Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin, Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma Kidney Cancer Management, : Peritoneal Mesothelioma: Pleural Multiple Myeloma Myelodysplastic Syndromes Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Myeloproliferative Neoplasms Neuroblastoma

https://www.nccn.org/guidelines/permission-to-cite-or-use-nccn-content

Resume Screening

Hepatobiliary Cancers Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma, Mesothelioma: Pleural Multiple Myeloma Myelodysplastic Syndromes Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Myeloproliferative Neoplasms Neuroblastoma, and Thymic Carcinomas Thyroid Carcinoma Uterine Neoplasms Vulvar Cancer Waldenström, Myeloproliferative Neoplasms Nasopharyngeal Cancer Nausea and Vomiting Neuroendocrine

https://www.nccn.org/covid-19/resume-screening

Transparency Process

Panel Disclosures/Attendance Version: 1.2024 ( Uterine Neoplasms ) Date: 2023-06-30, ( Uterine Neoplasms ) Date: 2023-04-07 Meeting Evidence Panel Disclosures/Attendance Version: 2.2023 ( Uterine Neoplasms ) Date: 2023-03-21 Meeting Evidence Panel, Evidence Panel Disclosures/Attendance Version: 1.2023 ( Uterine Neoplasms ) Date, Version: 1.2023 ( Uterine Neoplasms ) Date: 2022-06-28 Meeting Evidence Panel

https://www.nccn.org/guidelines/guidelines-process/transparency-process-and-recommendations

Guidelines With Evidence Blocks

Version 2.2024 Hepatocellular Carcinoma Version 2.2023 Histiocytic Neoplasms Version, Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Version 1.2024 Myeloproliferative Neoplasms Version 1.2024 Neuroendocrine and Adrenal Tumors, Version 1.2024 Thyroid Carcinoma Version 1.2024 Uterine Neoplasms Version 1.2024

https://www.nccn.org/guidelines/guidelines-with-evidence-blocks

Chemotherapy Order Templates Reviewer Acknowledgement

, PharmD, BCOP Roswell Park Comprehensive Cancer Center Histiocytic Neoplasms Jeri Angelo, PharmD, BCOP UC Davis, Moffitt Cancer Center Myeloproliferative Neoplasms, of Michigan Rogel Cancer Center Uterine Neoplasms Nadeem R. Abu

https://www.nccn.org/compendia-templates/nccn-templates-main/nccn-chemotherapy-order-reviewer-engagement

Submission Request History

on 10/17/2019 Nivolumab for Uterine Neoplasms Submitted by Bristol-Myers Squibb Company on 12/04/2019 Pembrolizumab for Uterine Neoplasms Submitted by Merck & Co., Inc, ., Inc. on 04/29/2020 Pembrolizumab dosing for Uterine Neoplasms Submitted by Merck & Co., Inc. on 04/29/2020 Systemic Therapy Table Headings for Uterine Neoplasms Submitted, . on 06/17/2020 Pembrolizumab for Uterine Neoplasms Submitted by Merck & Co., Inc. on 06/17/2020

https://www.nccn.org/guidelines/submissions-request-to-the-guidelines-panels/submission-request-history

Annual Report 2023

neoplasms. These clinical resources were also translated into Chinese by leading experts in the region

https://www.nccn.org/docs/default-source/about/annual-report-2023.pdf?sfvrsn=8411082_31